Sánchez-Tadeo MT, Estrada-Moreno BE, Castañeda-Chávez A, Flores-Martínez CA

Language: Spanish
References: 14
Page: 37-43
PDF size: 340.59 Kb.

ABSTRACT

The infection caused by Histoplasma capsulatum in the immunosuppressed host can affect a myriad of systems; the range of clinical manifestations in the primary cutaneous infection is wide; the pathological examination with appropriate staining showing the microorganism is enough for the diagnosis. We present a case series obtained between 2021-2023 which includes ten patients, all immunosuppressed, mostly men, in the age range of 27 to 65 years, seen in the outpatient clinic with a widespread, chronic dermatosis and diagnosed through biopsy and pathological examination.

REFERENCES

1. Araúz AB, Papineni P. Histoplasmosis. Infect Dis Clin North Am. 2021;35(2):471-491. doi: 10.1016/j.idc.2021.03.011. PMID: 34016287.

2. Gómez-Santana LV, Torre AC, Hernández BA, Volonteri VI, Laura B, Luis-Galimberti R. Mucocutaneous manifestations of infection by Histoplasma capsulatum in HIV-negative immunosuppressed patients. Actas Dermosifiliogr (Engl Ed). 2018;109(4):e27-e32. doi: 10.1016/j.ad.2017.08.006.

3. Tobón AM, Agudelo CA, Rosero DS, Ochoa JE, De Bedout C, Zuluaga A, et al. Disseminated histoplasmosis: a comparative study between patients with acquired immunodeficiency syndrome and non-human immunodeficiency virus-infected individuals. Am J Trop Med Hyg. 2005;73(3):576-582.

4. Fernández ACM, Illnait ZMT, Martínez MG, Perurena LMR, Monroy VE. Una actualización acerca de histoplasmosis. Rev Cubana Med Trop. 2011;63(3):189-205. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0375-07602011000300001&lng=es.

5. Mittal J, Ponce MG, Gendlina I, Nosanchuk JD. Histoplasma capsulatum: mechanisms for pathogenesis. Curr Top Microbiol Immunol. 2019;422:157-191. doi: 10.1007/82_2018_114.

6. Caceres DH, Valdes A. Histoplasmosis and tuberculosis co-occurrence in people with advanced HIV. J Fungi (Basel). 2019;5(3):73. doi: 10.3390/jof5030073.

7. Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71(6):1367-1376. doi: 10.1093/cid/ciz1008.

8. Ferreira MS, Borges AS. Histoplasmose [Histoplasmosis]. Rev Soc Bras Med Trop. 2009;42(2):192-198.

9. Buitrago MJ, Martín-Gómez MT. timely diagnosis of histoplasmosis in non-endemic countries: a laboratory challenge. Front Microbiol. 2020;11:467. doi: 10.3389/fmicb.2020.00467.

10. Mittal J, Ponce MG, Gendlina I, Nosanchuk JD. Histoplasma capsulatum: mechanisms for pathogenesis. Curr Top Microbiol Immunol. 2019;422:157-191. doi: 10.1007/82_2018_114.

11. Azar MM, Hage CA. Laboratory diagnostics for histoplasmosis. J Clin Microbiol. 2017;55(6):1612-1620. doi: 10.1128/JCM.02430-16.

12. Drak-Alsibai K, Couppié P, Blanchet D, Adenis A, Epelboin L, Blaizot R, et al. Cytological and histopathological spectrum of histoplasmosis: 15 years of experience in French Guiana. Front Cell Infect Microbiol. 2020;10:591974. doi: 10.3389/fcimb.2020.591974.

13. Batista JM, Martins MAP, Bertollo CM. Primary cutaneous histoplasmosis difficult to treat in immunocompetent patient: case report and literature review. Einstein (Sao Paulo). 2021;19:eRC5488. doi: 10.31744/einstein_journal/2021RC5488.

14. Johnson PC, Wheat LJ, Cloud GA, Goldman M, Lancaster D, Bamberger DM, et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med. 2002;137(2):105-109. doi: 10.7326/0003-4819-137-2-200207160-00008.